Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

Inclusion Criteria: * Disease duration of 5 years or less and documented clinical worsening (clinical or ENMG or disability) over the past 24 months * IgM gammopathy, either MGUS or Waldenstrom Macroglobulinemia (WM) * Demyelinating polyneuropathy according to European Federation of Neurological Societies/Peripheral Nerve Society guidelines for chronic inflammatory demyelinating polyneuropathy on nerve conduction studies. * Anti-MAG titre of 10 000 BTU or more * Total INCAT score of 1 point or more at baseline * Absence of immunoglobulin treatment within 3 months prior to inclusion. * Absence of immunosuppressive therapy within 6 months prior to inclusion, including steroid therapy of 2 months or more as part of the management of neuropathy. * Negative β-human chorionic gonadotropin (HCG) in women of childbearing potential * Women of childbearing potential must agree to use contraception for 365 days following administration of rituximab. Exclusion Criteria: * \- Unable to give informed consent * History of severe allergic or anaphylactic reaction to chimeric monoclonal antibody * Hypersensitivity known to one of the compounds of polaramine or methylprednisolone * Previous treatment with rituximab * Diseases known to cause polyneuropathy (e.g. diabetes, uncontrolled thyroid disease, vitamin B1 or B12 deficiency, renal (GFR \< 60ml ml/min/1,73 m2- Modification of Diet in Renal Disease (MDRD) formula) or liver disorder, myeloma, amyloidosis, cryoglobulinemia) * Indication of…